8-K: REGENXBIO Reports Q1 2026 Results, Positive RGX-202 Data

REGENXBIO announced positive topline results from its pivotal Phase III AFFINITY DUCHENNE study of RGX-202 for Duchenne muscular dystrophy, achieving its primary endpoint with high statistical significance.

Summary

• REGENXBIO reported its first quarter 2026 financial results and provided operational highlights.
• The company announced positive topline results from the pivotal Phase III AFFINITY DUCHENNE study of RGX-202, a gene therapy for Duchenne muscular dystrophy.
• RGX-202 achieved its primary endpoint with 93% of patients showing microdystrophin expression above 10% (p<0.0001) and demonstrated a statistically significant correlation between expression and functional improvement.
• The company is preparing for a potential accelerated approval of RGX-202 in 2027.
• Collaboration with AbbVie on surabgene lomparvovec (sura-vec) for diabetic retinopathy is progressing, with the first patient dosed expected in Q2 2026, triggering a $100 million milestone payment.
• Topline data from pivotal trials of sura-vec for wet AMD is expected in Q4 2026.
• The clinical hold for RGX-121 for Hunter syndrome has been lifted, and REGENXBIO is engaging with the FDA regarding a path forward.
• The company ended the quarter with $150.5 million in cash, cash equivalents, and marketable securities, expecting this to fund operations into early 2027.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, driven by highly encouraging clinical trial data for RGX-202 and significant progress in partnered programs, despite the ongoing net loss typical for a development-stage biotech.

Positives

• Positive topline results from the pivotal Phase III AFFINITY DUCHENNE trial of RGX-202, meeting the primary endpoint with high statistical significance (93% of patients achieved >10% microdystrophin expression, p<0.0001).
• Statistically significant correlation demonstrated between RGX-202 microdystrophin expression and functional improvement (NSAA) at one year post-treatment.
• RGX-202 was well-tolerated with a favorable interim safety profile, with no GGT or bilirubin levels exceeding the upper limit of normal up to one year post-treatment.
• The FDA has lifted the clinical hold on RGX-121 for Hunter syndrome.
• First patient dosed in the Phase IIb/III NAAVIGATE study for diabetic retinopathy is expected in Q2 2026, triggering a $100 million milestone payment from AbbVie.
• Topline data from ATMOSPHERE and ASCENT pivotal trials of sura-vec for wet AMD are expected in Q4 2026.
• REGENXBIO expects its cash position to fund operations into early 2027.

Negatives

• Revenues decreased to $6.4 million for Q1 2026 from $89.0 million in Q1 2025, primarily due to the recognition of a $70.0 million upfront license in the prior year and a decrease in ZOLGENSMA royalty revenues.
• Net loss for Q1 2026 was $90.1 million, compared to a net income of $6.1 million in Q1 2025.
• Cash, cash equivalents, and marketable securities decreased to $150.5 million as of March 31, 2026, from $240.9 million as of December 31, 2025, due to cash used in operating activities, including a $10.0 million non-recurring payment for a settlement agreement.

Risks

• The FDA has recommended a randomized controlled trial for RGX-202, although it has guided that externally controlled trials may be adequate if the treatment effect is sufficiently large.
• The company faces risks related to the timing, enrollment, commencement, completion, and success of clinical trials.
• There are uncertainties regarding the interpretation of clinical data, with the possibility that interim or early data may not be indicative of final results.
• Regulatory authorities may interpret data differently than REGENXBIO.
• The company's ability to obtain and maintain regulatory approval for product candidates is subject to risks.
• Intellectual property protection for product candidates and technology is a potential risk.
• Trends and challenges in the business and markets in which REGENXBIO operates could impact results.
• The size and growth of potential markets and the ability to serve them are subject to risk.

Future Outlook

REGENXBIO expects its current cash position to fund operations into early 2027. The company is preparing for a potential accelerated approval and commercial launch of RGX-202 in 2027. Global regulatory submissions for surabgene lomparvovec (sura-vec) are expected in 2027. The company anticipates a $100 million milestone payment from AbbVie upon the first patient dosed in the Phase IIb portion of the NAAVIGATE study in Q2 2026.

Management Comments

• "REGENXBIO enters a transformative year with positive momentum, reaching significant late-stage milestones to support our potential first- and best-in-class gene therapies," said Curran Simpson, President and Chief Executive Officer.
• "On our mission to bring meaningful new therapies to rare disease communities facing limited options, we remain focused on advancing RGX-202 for Duchenne toward potential BLA submission and are excited to share topline pivotal data in our webcast today; we also continue engaging with the FDA regarding a potential path forward for RGX-121 for Hunter syndrome."
• "In chronic retinal diseases, we are executing against our multi-indication strategy and preparing for the Phase 3 wet AMD readout with partner AbbVie. Additionally, we continue harnessing internal manufacturing capabilities to support anticipated commercial needs."
• "We remain well-positioned to capitalize on several near-term, high-value opportunities and bring these highly differentiated treatments to patients."
• "RGX-202 is the first gene therapy in development for Duchenne to demonstrate strong, statistically significant correlation between microdystrophin expression and functional improvement, a landmark distinction in the field," said Steve Pakola, M.D., Chief Medical Officer.
• "Todays topline results underscore how our novel construct and differentiated therapeutic approach support a favorable safety profile and potential clinical benefit, including in older patients where progressive decline is expected. These data support the potential of RGX-202 to become a best-in-class gene therapy for Duchenne patients."

Industry Context

StockSavvy.ai notes that REGENXBIO's positive RGX-202 data aligns with the broader trend in the gene therapy sector towards addressing rare genetic diseases with potentially curative, one-time treatments. The company's progress in Duchenne muscular dystrophy and its collaborations in retinal diseases highlight the increasing sophistication and late-stage advancement within the AAV gene therapy space.

Comparison to Industry Standards

• The achievement of the primary endpoint in the RGX-202 Phase III trial with 93% of patients exceeding 10% microdystrophin expression (p<0.0001) sets a high bar for efficacy in Duchenne gene therapies.
• The statistically significant correlation between microdystrophin expression and functional improvement (NSAA) at one year post-treatment is a critical validation of the surrogate endpoint, a key consideration for regulatory approval and a benchmark for other gene therapy programs.
• The favorable safety profile, with key liver enzyme markers remaining within normal limits up to one year post-treatment, is competitive within the gene therapy landscape where managing immune responses and potential toxicities is paramount.
• The $100 million milestone payment from AbbVie upon dosing the first patient in the Phase IIb/III NAAVIGATE study is a significant validation of the surabgene lomparvovec program and aligns with typical partnership structures in the biopharmaceutical industry.

Stakeholder Impact

• Shareholders: Positive clinical data and strategic progress may lead to increased investor confidence and potential share price appreciation. The company's cash runway into early 2027 provides operational stability.
• Patients with Duchenne Muscular Dystrophy: Positive RGX-202 data offers hope for a new, potentially best-in-class therapy that addresses the underlying cause of the disease, with potential for accelerated approval.
• Patients with Diabetic Retinopathy and Wet AMD: Progress in the surabgene lomparvovec program, including expected milestone payments and data readouts, indicates continued development towards new treatment options.
• Patients with Hunter Syndrome (MPS II): The lifting of the clinical hold on RGX-121 is a positive step towards potentially advancing this treatment option.
• Partners (AbbVie, Nippon Shinyaku): Continued progress in collaborative programs validates the partnerships and is expected to lead to milestone payments and future revenue streams.

Next Steps

• Engage with the FDA regarding a potential path forward for RGX-121.
• Dose first patient in the Phase IIb/III NAAVIGATE study for diabetic retinopathy (expected Q2 2026).
• Complete dosing in all 60 patients across the pivotal and confirmatory RGX-202 trials (expected mid-year 2026).
• Share topline data from ATMOSPHERE and ASCENT pivotal trials of sura-vec for wet AMD (expected Q4 2026).
• Prepare for potential accelerated approval and commercial launch of RGX-202 (potential 2027).
• Submit global regulatory applications for sura-vec (expected 2027).

Key Dates

Recommendation

The strong positive clinical data for RGX-202, meeting its primary endpoint with high statistical significance and demonstrating a correlation with functional improvement, combined with the lifting of the RGX-121 clinical hold and progress in partnered programs, presents a compelling risk-reward profile. The company's cash runway into early 2027 provides a stable foundation for continued development towards potential approvals and commercialization, making it an attractive investment opportunity.

Keywords

REGENXBIO, RGX-202, Duchenne Muscular Dystrophy, Gene Therapy, Clinical Trial, Phase III, AbbVie, Sura-vec